Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Trial ID or NCT#

NCT00557193

Status

not recruiting iconNOT RECRUITING

Purpose

This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.

Official Title

A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)

Eligibility Criteria

Ages Eligible for Study: Younger than 1 Year
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

Investigator(s)

Neyssa Marina

Contact us to find out if this trial is right for you.

Contact

Pediatric Hematology/Oncology
650-723-5535